Internal high linear energy transfer (LET) targeted radiotherapy for cancer

Physics in Medicine and Biology

Volumn 51, Issue 13, 2006, Pages

  Allen, Barry J ^a,b,c,d,e,f  

^a St George Cancer Care Centre   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ACPSEM ^*  (Australia)

^d Institute of Physics   (Australia)

^e Asia Oceania Federation of Medical Physics   (Australia)

^f International Organisation of Medical Physics   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LINEAR ENERGY TRANSFER (LET); METASTATIC CANCER; PALLIATION;

CHEMOTHERAPY; DNA; MEDICAL APPLICATIONS; ONCOLOGY; TISSUE;

RADIOTHERAPY;

4 DIHYDROXYBORYLPHENYLALANINE; ACTINIUM 225; BISMUTH 213; BORON; BORON DERIVATIVE; DEUTERIUM OXIDE; DNA; GADOLINIUM; PROTOPORPHYRIN; TERBIUM; UNCLASSIFIED DRUG;

ALPHA RADIATION; AUSTRALIA; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; DNA STRAND BREAKAGE; DOSIMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LINEAR ENERGY TRANSFER; MELANOMA; MONTE CARLO METHOD; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANIMALS; BORON NEUTRON CAPTURE THERAPY; CLINICAL TRIALS; HUMANS; LINEAR ENERGY TRANSFER; NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY, HIGH-ENERGY;

EID: 33745500490     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/51/13/R19     Document Type: Review

References (104)

1. Allen B J 1993 Neutron capture therapy for cancer and the proposed new research reactor Cancer Forum 17 250-2
2. Allen B J 1999a Can alpha-immunotherapy succeed where other systemic modalities have failed? Nucl. Med. Commun. 20 205-7
3. Allen B J 1999b Targeted alpha therapy: evidence for efficacy of alpha immunoconjugates in the management of micrometastatic cancer Australas. Radiol. 43 480-6
4. Allen B J, Brown J K, Mountford M H, Tamat S R, Patwardhan A, Moore D E, Ichihashi M, Mishima Y and Kahl S B 1989a In vitro and in vivo studies of boron conjugated melanoma affined biochemicals Strahlenther. Onkol. 165 163-5
5. Allen B J and Charlton D E 1994 Dose sparing of capillary endothelial cells for BSH and BPA: a model for capillary truncation Cancer Neutron Capture Therapy, Proc 6th Int. Symp. Neutron Capture Therapy for Cancer ed Y Mishima (Kobe: Plenum) pp 479-83
6. Allen B J, Coates A S, McCarthy W H, Mameghan H, Mishima Y and Ichihashi M 1989b Thermal neutron capture therapy: the Japanese-Australian clinical trial for malignant melanoma Basic Life Sci. 50 69-73
7. Allen B J, Corderoy-Buck S, Mallesch J L, Crotty K and Moore D E 1992 Local control of subcutaneous murine melanoma xenografts in nude mice by neutron capture therapy Melanoma Res. 2 253-62
8. Allen B J, Goozee G, Sarkar S, Beyer G, Morel C and Byrne A P 2001a Production of terbium-152 by heavy ion reactions and proton induced spallation Appl. Radiat. Isot. 54 53-8
9. Allen B J, McGregor B J and Martin R F 1989c Neutron capture therapy with gadolinium-157 Strahlenther. Onkol. 165 156-8
10. Allen B J et al 2004 Targeted alpha therapy for cancer Phys. Med. Biol. 49 3703-12
11. Allen B J et al 2006 Intralesional targeted alpha therapy for metastatic melanoma Cancer Biol. Therapy 4 1318-24
12. Allen B J, Rizvi S M and Tian Z 2001b Preclinical targeted alpha therapy for subcutaneous melanoma Melanoma Res. 11 175-82
13. Allen B J, Tian Z, Rizvi S M A, Li Y and Ranson M 2003 Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled- plasminogen activator inhibitor type 2 Br. J. Cancer 88 944-50
14. Barth R et al 1997 Boron neutron capture therapy of brain tumours: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption Cancer Res. 579-36 112
15. Barth R F 2003 A critical assessment of boron neutron capture therapy: an overview J. Neuro.-Oncol. 62 1-5
16. Barth R F, Coderre J A, Vicente M G H and Blue T E 2005 Boron neutron capture therapy of cancer: current status and future prospects Clin. Cancer Res. 11 3987-4002
17. 149Tb for medical application Radiochim. Acta 90 247-52
18. Beynon T, Forcey K S, Green S, Cruickshank G and James N 2002 Status of the Birmingham accelerator based BNCT facility Research and Development in Neutron Capture Therapy ed M W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore, International Proceedings Division) pp 225-8
19. Blackburn B W, Yanch J C and Klinkowstein R E 1998 Development of a high-power water cooled beryllium target for use in accelerator-based boron neutron capture therapy Med. Phys. 25 1967-74
20. Blagojevic N, Storr G, Allen B J, Hatanaka H and Nakagawa H 1994 Role of heavy water in boron neutron capture therapy Topics in Dosimetry and Treatment Planning for Neutron Capture Therapy ed R G Zamenhof et al (Madison, USA: Advanced Medical Publishing) pp 125-34
21. Blaumann H, Larrieu O C, Longhino J M and Albornoz A F 2001 NCT facility development and beam characterisation at the RA-6 Reactor Frontiers in Neutron Capture Therapy vol 1 ed M Hawthorne, K Shelly and R J Wiersema (New York: Kluwer) pp 313-7
22. 90Y Int. J. Radiat. Oncol. Biol. Phys. 10 341-8
23. Blue T E and Yanch J 2003 Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors J Neurooncol. 62 19-31
24. Burian J et al 2002 Report on the first patient group of the phase 1 BNCT trial at the LVR-15 reactor Research and Development in Neutron Capture Therapy ed W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore) pp 1107-12
25. Burlon A et al 2002 Optimization of a neutron production target and beam shaping assembly based on the 7Li(p.n)7 Be reaction Research and Development in Neutron Capture Therapy ed M W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore, International Proceedings Division) pp 229-34
26. Busse P M et al 2003 A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease J. Neurooncol. 62 111-21
27. Capala J et al 2003 Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden J. Neurooncol. 62 135-44
28. Carolan M, Wallace S A, Allen B J, Rosenfeld A, Mather J N, Meriaty H, Stecher-Rasmussen F and Moss R L 1994 Validation of Monte Carlo dose planning calculations by epithermal beam dose distribution measurements in phantoms Proc. 6th Int. Symp. Neutron Capture Therapy for Cancer ed Y Mishima (Kobe: Plenum) pp 303-10
29. Coderre J A et al 1997 Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results J. Neurooncol. 33 141-52
30. Culbertson C N, Green S, Mason A J, Picton D, Baugh G, Hugtenberg R P, Yin Z, Scott M C and Nelson J M 2004 In phantom characterisation studies at the Birmingham accelerator epithermal neutron source (BAGINS) BNCT facility Appl. Radiat. Isot. 61 733-8
31. Diaz A Z 2003 Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view J. Neurooncol. 62 101-9
32. Fairchild R G et al 1989 Installation and testing of an optimized epithermal neutron beam at the Brookhaven Medical Research Reactor (BMRR) Proc. Workshop on Neutron Beam Design, Development and Performance for Neutron Capture Therapy (Cambridge, MA: MIT) pp 29-31
33. Fairchild R G et al 1990 An optimised epithermal neutron beam for neutron capture therapy (NCY) at the Brookhaven Medical Research Reactor (BMRR) Progress in Neutron capture Therapy ed B J Allen, D E Moore and B V Harrington (Sydney: Plenum) pp 1-6
34. Finn R D et al 1997 Refinements and improvements for Bi-213 production and use as a targeted therapeutic radiopharmaceutical J. Labelled Compds Radiopharm. 40 293
35. 7Li reaction in cells and tissues and its implication for boron neutron capture therapy Radiat. Res. 111 14-25
36. Giusti V E J 2002 Neutronic feasibility study of an accelerator-based thermal neutron irradiation cavity Research and Development in Neutron Capture Therapy ed M W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore, International Proceedings Division) pp 305-8
37. Godwin J T, Farr L E, Sweet W H and Robertson J S 1955 Pathological study of eight patients with glioblastoma multiforme treated by neutron capture therapy using boron-10 Cancer Biol. Therapy 8 601-15
38. Harrington B V 1987 Optimisation of an epithermal beam for HIFAR for boron neutron capture therapy ANSTO/E662
39. 213Bi, and their decay chain related radionuclides, for therapeutic applications Chem. Rev. 101 2019-36
40. Hatanaka H 1991 Boron neutron capture therapy for brain tumours Glioma ed A B M F Karin and E Laws (Berlin: Springer) pp 233-49
41. Hatanaka H and Nakagawa Y 1994 Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy Int. J. Radiat. Oncol. Biol. Phys. 28 1061-6
42. Hawk A, Blue T, Woolard J and Gupta N 2002 Effects of target thickness on neutron field quality for an ABNS. Research and development in neutron capture therapy Research and Development in Neutron Capture Therapy ed M W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore, International Proceedings Division) pp 253-57
43. Hawk A B T, Woolard J and Gupta N 2002 Effects of target thickness on neutron field quality for an ABNS. Research and development in neutron capture therapy Research and Development in Neutron Capture Therapy ed M W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore, International Proceedings Division) pp 253-57
44. Hill J, Kahl S B, Stylli S S, Nakamura Y, Koo M S and Kaye A H 1995 Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer Proc. Natl Acad. Sci. USA 92 12126-30
45. Joensuu H et al 2003 Boron neutron capture therapy of brain tumors: clinical trials at the Finnish Facility using boronophenylalanine J. Neurooncol. 62 123-34
46. Jurcic J G et al 2002 Targeted alpha particle immunotherapy for myeloid leukemia Blood 100 1233-9
47. Kahl S B, Tibbitts J and Fike J 1996 Toxicology and pharmacokinetics of BOPP in a canine model Cancer Neutron Capture Therapy ed Y Mishina (Kobe: Plenum) pp 605-10
48. Kaplan G I, Rosenfeld A B, Allen B J, Booth J T, Carolan M G and Holmes-Siedle A 2000 Improved spatial resolution by MOSFET dosimetry of an x-ray microbeam Med. Phys. 27 239-44
49. Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M and Yura Y 2004 Effectiveness of BNCT for recurrent head and neck malignancies Appl. Radiat. Isot. 61 1069-73
50. 7Li reaction Radiat. Res. 61 304-15
51. Kobayashi T, Sakurai Y, Kanda K, Fujita Y and Ono K 2000 The remodeling and basic characteristics of the heavy water neutron irradiation facility of the Kyoto University Research Reactor, mainly for neutron capture therapy Nucl. Technol. 131 354-78
52. 7Be reaction for NCT based on in-phantom dose distribution Research and Development in Neutron Capture Therapy ed M W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore, International Proceedings Division) pp 241-6
53. 213Bi-Herceptin alpha-conjugate Cancer Lett. 205 161-71
54. Li Y, Rizvi S M A, Ranson M and Allen B J 2002 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model Br. J. Cancer 86 1197-203
55. Mallesch J L, Moore D E, Allen B J, McCarthy W H, Jones R and Stening W A 1994 The pharmacokinetics of p-Boronophenylalanine.fructose in human patients with glioma and metastatic melanoma Int. J. Radiat. Oncol. Biol. Phys. 28 1183-8
56. 157Gd Int. J. Radiat. Biol. 54 205-8
57. Miederer M et al 2003 Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein Radiat. Res. 159 612-20
58. Mishima Y 1996 Selective thermal neutron capture therapy of cancer cells using their specific metabolic activities-melanoma as prototype Cancer Neutron Capture Therapy (New York: Plenum) pp 1-26
59. 10B molecule-melanoma cell interaction from in vitro to first clinical trial Proc. 2nd Japan-Australia International Workshop on Thermal Neutron Capture Therapy for Malignant Melanoma (Kobe, 1987) Pigment Cell Research vol 2 pp 226-34
60. Moore D E, Stretch J R, Dawes A C, Cockayne D, Allen B J and Constantine G 1990 Uptake of boronated monoclonal antibodies by melanoma cells visualised by track etch autoradiography and electron energy loss spectroscopy Progress in Neutron Capture Therapy for Cancer ed B J Allen, D E Moore and B V Harrington (Sydney: Plenum) pp 335-8
61. Morris G M, Coderre J A, Hopewell J W, Micca P L and Rezvani M 1994 Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium Radiother. Oncol. 32 144-53
62. Moss R, Stecher-Rasmussen F, Ravensburg K, Constantine G and Watkins P 1990 Design, construction and installation of an epithermal neutron beam for BNCT at the high flux reactor Petten Progress in Neutron Capture Therapy ed B J Allen, D E Moore and B V Harrington (New York: Plenum) pp 63-6
63. Nigg D, Wheeler F J, Wessol D E, Capala J and Chadha M 1997 Computational dosimetry and treatment planning for boron neutron capture therapy of glioblastoma multiforme J. Neurooncol. 33 93-104
64. Nigg D et al 2002 Initial neutronic performance assessment of an epithermal neutron beam for neutron capture therapy research at Washington State University Research and Development in Neutron Capture Therapy ed M W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore, International Proceedings Division) pp 135-9
65. Nilsson S, Larsen R H, Fosså S D, Balteskard L, Borch K W, Westlin J E, Salberg G and Bruland O S 2005 First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases Clin. Cancer Res. 11 4451-59
66. Perry J et al 1997 Challenges in the design and conduct of phase III brain tumor therapy trials Neurology 49 912-17
67. Pinelli T et al 2002 TAOrMINA: from the first idea to the application to the human liver Research and Development in Neutron Capture Therapy ed W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi) pp 1065-72
68. Prashar J K and Moore D E 1993a Synthesis of carboranyl phenylalanine for potential use in neutron capture therapy of melanoma J. Chem. Soc. Perkin Trans. 1 1051-3
69. Prashar J K, Lama D and Moore D E 1993b Synthesis of dihydroxycarboranyl phenylalanine for potential use in neutron capture therapy of melanoma Tetrahedron Lett. 34 6799-800
70. 213Bi Labeled PAI2 for the control of micrometastatic pancreatic cancer Clin. Exp. Metastasis 22 575-86
71. Riley K, Binns P and Harling O 2003 Performance characteristics of the MIT fission converter based epithermal neutron beam Phys. Med. Biol. 48 943-58
72. Rizvi S M A, Allen B J, Tian Z, Li Y, Goozee G and Sarkar S 2001 In vitro and preclinical studies of targeted alpha therapy for colorectal cancer Colorectal Dis. 3 345-53
73. Rizvi S M A, Henniker A J, Goozee G and Allen B J 2002 In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes Leuk. Res. 26 37-43
74. Rizvi S M A, Sarkar S, Goozee G and Allen B J 2000 Radioimmunoconjugates for targeted alpha therapy of malignant melanoma Melanoma Res. 10 281-9
75. Rogus R, Harling O K, Olmez I and Wirdzek S 1990 Boron-10 prompt gamma analysis using a diffracted neutron beam Progress in Neutron Capture Therapy for Cancer ed B J Allen, D E Moore and B V Harrington (Sydney: Plenum) pp 283-316
76. Rosenthal M et al 2001 Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin J. Clin. Oncol. 19 519-24
77. Rosenthal M, Kavar B, Uren S and Kaye A H 2003 Promising survival in patients with high-grade gliomas following therapy with a novel boronated porphyrin J. Clin. Neurosci. 10 425-7
78. Rydin R A, Deutsch O L and Murray B W 1976 The effect of geometry on capillary wall dose for boron neutron capture therapy Phys. Med. Biol. 21 134-8
79. Sakurai Y, Kobayashi T and Ono K 2002 Study on accelerator-base neutron irradiation field aiming for wider application in BNCT-spectrum shift and regional filtering Research and Development in Neutron Capture Therapy ed M W Sauerwein, R Moss and A Wittig (Bologna: Monduzzi Editore, International Proceedings Division) pp 259-63
80. Setiawan Y, Halliday G M, Harding A J, Moore D E and Allen B J 1995 Effect of L-10B-p-boronophenylalanine-fructose and the boron neutron capture reaction on mouse brain dopaminergic neurons Cancer Res. 55 874-7
81. Setiawan Y, Moore D E and Allen B J 1996 Selective uptake of boronated low-density lipoprotein in melanoma xenografts achieved by diet supplementation Br. J. Cancer 74 1705-8
82. Setiawan Y, Rise T and Moore D E 1994 FTIR spectrometry for the assay of polyhedral boron compounds in plasma and pharmaceutical formulations Pharmaceut. Res. 11 723-7
83. Setiawan Y, Smith M, Moore D E and Allen B J 1994 Pharmacokinetics and effects of neutron capture therapy of melanoma xenografts after administration of boronated low density lipoprotein Cancer Neutron Capture Therapy, Proc 6th Int. Symp. Neutron Capture Therapy for Cancer ed Y Mishima (New York: Plenum) pp 599-604
84. Snyder H R, Reedy A J and Lennarz W J 1958 Synthesis of aromatic boronic acids, aldehydo boronic acids and a boronic acid analog of tyrosine J. Am. Chem. Soc. 80 835-8
85. Soloway A H, Hatanaka H and Davis M A 1967 Penetration of brain and brain tumor: VII. Tumor-binding sulfhydryl boron compounds J. Med. Chem. 10 714-7
86. Song Y J, Qu C F, Rizvi S M A, Li Y, Robertson G, Raja C, Morgenstern A, Apostolidis C, Perkins A C and Allen B J 2005 Cytotoxicity of PAI2, C595 and herceptin vectors labeled with the alpha-emitting radioisotope bismuth-213 for ovarian cancer cell monolayers and clusters Cancer Lett. 234 176-83
87. Stretch J R, Moore D E, Allen B J and Constantine G 1992 Boronated monoclonal antibody for neutron capture therapy of melanoma: specificity retention shown by autoradiography of tissue sections Antibody Immunoconjugates Radiopharm. 5 261-5
88. Tamat S R, Moore D E and Allen B J 1987 Determination of boron in biological tissues by inductively coupled plasma atomic emission spectrometry Anal. Chem. 59 2161-4
89. Tamat S R, Moore D E and Allen B J 1989a Determination of the concentration of complex boronated compounds in biological tissues by inductively coupled plasma atomic emission spectrometry Pigment Cell Res. 2 281-5
90. Tamat S R, Patwardhan A, Moore D E, Kabral A, Bradstock K, Hersey P and Allen B J 1989b Boronated monoclonal antibodies for potential neutron capture therapy of malignant melanoma and leukaemia Strahlenther. Onkol. 165 145-7
91. Wallace S A, Allen B J and Mathur J 1994 Monte Carlo neutron treatment planning calculations: modelling from CT scans with variable voxal size Cancer Neutron Capture Therapy, Proc. 6th Int. Symp. Neutron Capture Therapy for Cancer ed Y Mishima (Kobe: Plenum) pp 295-302
92. Wallace S A, Allen B J and Mathur J N 1995a Monte Carlo calculations of epithermal boron neutron capture therapy with heavy water Phys. Med. Biol. 40 1599-608
93. Wallace S A, Mathur J N and Allen B J 1995b The influence of heavy water on boron requirements for neutron capture therapy Med. Phys. 22 585-90
94. Wilson J G 1990 Carborane compounds for neutron capture therapy of malignant melanoma Progress in Neutron Capture Therapy ed B J Allen, D E Moore and B V Harrington (Sydney: Plenum) pp 227-30
95. Wittig A et al 2002 Current clinical results of the EORTC-study 11961 Research and Development in Neutron Capture Therapy ed W Sauerwein, R Moss and A Wittig (Monduzzi Editore: Essen) pp 1117-22
96. Wootton P, Risler R, Livesey J, Brossard S, Laramore G and Griffin T 1992 Boron neutron capture enhancement of the tumor dose in fast neutron therapy beams Progress in Neutron capture Therapy for Cancer ed B J Allen, D E Moore and B V Harrington (Sydney: Plenum) pp 195-8
97. Yamamoto K et al 2000 Characteristics of neutron beams for BNCT.rapy; 2 Proc. 9th Symp. on Neutron Capture (Osaka) pp 243-44
98. Yanch C J, Zamenhof R G, Wierzbicki J and Maruyama Y 1990 Comparison of dose distributions with B-10 augmentation near linear sources of Cf-252 obtained by Monte Carlo simulation and by experimental measurement Progress in Neutron Capture Therapy ed B J Allen, D E Moore and B V Harrington (Sydney: Plenum) pp 191-4
99. Yoshina K, Suzuki A, Mori Y, Kakihana H, Honda C, Mishima Y, Kobayashi T and Kanda K 1989 Improvement of the solubility of p-boronphenylalanine by complex formation with monosaccharides Strahlenther. Onkol. 165 127-9
100. Zalutsky M R 2005 Current status of therapy of solid tumours: brain tumour therapy J. Nucl. Med. 46 151S-6S
101. Zamenhof R, Redmond E, Solares G, Katz D, Riley K, Kiger S and Harling O 1996 Monte Carlo based treatment planning for boron neutron capture therapy using custom designed models automatically generated from CT data Int. J. Radiat. Oncol. Biol. Phys. 35 383-97
102. 7Li(p, n) reaction Australas. Phys. Eng. Sci. Med. 21 193-9
103. 7Li(p,n) reaction near threshold Phys. Med. Biol. 45 59-67
104. Zalutsky M R and Bigner D D 1996 Radioimmunotherapy with alpha-emitting radioimmunoconjugates Acta Oncol. 35 373-9